Akter Shahina, Shahab Muhammad, Sarkar Md Murshed Hasan, Hayat Chandni, Banu Tanjina Akhtar, Goswami Barna, Jahan Iffat, Osman Eshrar, Uzzaman Mohammad Samir, Habib Md Ahashan, Shaikh Aftab Ali, Khan Md Salim
Bangladesh Council of Scientific & Industrial Research (BCSIR), Dhaka, Bangladesh.
State Key Laboratories of Chemical Resources Engineering, Beijing University of Chemical Technology, Beijing, 100029, China.
J Genet Eng Biotechnol. 2022 Sep 20;20(1):136. doi: 10.1186/s43141-022-00410-8.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic which has brought a great challenge to public health. After the first emergence of novel coronavirus SARS-CoV-2 in the city of Wuhan, China, in December 2019. As of March 2020, SARS-CoV-2 was first reported in Bangladesh and since then the country has experienced a steady rise in infections, resulting in 13,355,191 cases and 29,024 deaths as of 27 February 2022. Bioinformatics techniques are used to predict B cell and T cell epitopes from the new SARS-CoV-2 spike glycoprotein in order to build a unique multiple epitope vaccine. The immunogenicity, antigenicity scores, and toxicity of these epitopes were evaluated and chosen based on their capacity to elicit an immune response.
The best multi-epitope of the possible immunogenic property was created by combining epitopes. EAAAK, AAY, and GPGPG linkers were used to connect the epitopes. In several computer-based immune response analyses, this vaccine design was found to be efficient, as well as having high population coverage.
This research is entirely reliant on the development of epitope-based vaccines, and these in silico findings would represent a major step forward in the development of a vaccine that might eradicate SARS-CoV-2 in Bangladeshi patients.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是正在肆虐的2019冠状病毒病（COVID-19）大流行的病原体，给公共卫生带来了巨大挑战。2019年12月新型冠状病毒SARS-CoV-2首次在中国武汉市出现。截至2020年3月，孟加拉国首次报告了SARS-CoV-2感染病例，自那时起该国感染人数稳步上升，截至2022年2月27日，累计确诊病例达13355191例，死亡29024例。运用生物信息学技术从新型SARS-CoV-2刺突糖蛋白中预测B细胞和T细胞表位，以构建一种独特的多表位疫苗。基于这些表位引发免疫反应的能力，对其免疫原性、抗原性评分及毒性进行了评估和筛选。
通过组合表位创建了具有潜在免疫原性的最佳多表位。使用EAAAK、AAY和GPGPG接头连接这些表位。在多项基于计算机的免疫反应分析中，该疫苗设计被证明是有效的，且具有较高的人群覆盖率。
本研究完全依赖于基于表位的疫苗开发，这些计算机模拟研究结果将是开发可能根除孟加拉国患者体内SARS-CoV-2疫苗的重要一步。
